We have located links that may give you full text access.
N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART.
European Journal of Medical Research 2007 April 27
BACKGROUND: Studies suggest that highly active anti-retroviral therapy (HAART) prolongs life in HIV infected individuals and that HIV infected individuals increasingly suffer from cardiovascular complications. NT-proBNP has been shown to represent an indicator of cardiac function.
METHODS: 495 HIV infected individuals under HAART and 1980 blood donors (BD) were tested for N-terminal pro-B-type natriuretic peptide (NT-proBNP). NT-proBNP was performed by an automated electrochemiluminescence immunoassay (ECLIA) method.
RESULTS: HIV infected individuals had significantly higher NT-proBNP levels than age matched blood donors (18-29 y: median: 33 pg/ml HIV vs. 5 pg/ml BD; p = 0.0247; 30-39 y: median: 25 pg/ml HIV vs. 5 pg/ml BD; p = 0.0351; 40-49 y: median: 35.5 pg/ml HIV vs. 5 pg/ml BD; p < 0.0001; 50-59 y: median: 42 pg/ml HIV vs. 36 pg/ml BD; p = 0.3665; 60-69 y: median: 82.5 pg/ml HIV vs. 46 pg/ml BD; p = 0.0055) the effect was consistently found in all age and both gender groups. HIV infected individuals differed from the blood donor control group with respect to cardiovascular risk factors (hypertension, cardiovascular (CV) medication, diabetes mellitus, smoking status). In HIV infected individuals NT-proBNP levels did not correlate to cardiovascular risk factors including GFR except for C-reactive protein (CRP) levels using multivariate analysis. There was also no evidence for cardiotoxic effects due to HAART or specific antiretroviral drugs. High NT-proBNP levels were found in Hepatitis C virus (HCV) infected individuals who had received alpha-interferon therapy.
CONCLUSIONS: HIV infected individuals had higher NT-proBNP levels than age matched blood donors possibly as a result of a higher prevalence of general cardiovascular risk factors and HIV associated risk factors, the finding is consistent with an increased incidence of cardiovascular events described in HIV infected individuals. Further studies on the relationship to cardiovascular outcome are warranted.
METHODS: 495 HIV infected individuals under HAART and 1980 blood donors (BD) were tested for N-terminal pro-B-type natriuretic peptide (NT-proBNP). NT-proBNP was performed by an automated electrochemiluminescence immunoassay (ECLIA) method.
RESULTS: HIV infected individuals had significantly higher NT-proBNP levels than age matched blood donors (18-29 y: median: 33 pg/ml HIV vs. 5 pg/ml BD; p = 0.0247; 30-39 y: median: 25 pg/ml HIV vs. 5 pg/ml BD; p = 0.0351; 40-49 y: median: 35.5 pg/ml HIV vs. 5 pg/ml BD; p < 0.0001; 50-59 y: median: 42 pg/ml HIV vs. 36 pg/ml BD; p = 0.3665; 60-69 y: median: 82.5 pg/ml HIV vs. 46 pg/ml BD; p = 0.0055) the effect was consistently found in all age and both gender groups. HIV infected individuals differed from the blood donor control group with respect to cardiovascular risk factors (hypertension, cardiovascular (CV) medication, diabetes mellitus, smoking status). In HIV infected individuals NT-proBNP levels did not correlate to cardiovascular risk factors including GFR except for C-reactive protein (CRP) levels using multivariate analysis. There was also no evidence for cardiotoxic effects due to HAART or specific antiretroviral drugs. High NT-proBNP levels were found in Hepatitis C virus (HCV) infected individuals who had received alpha-interferon therapy.
CONCLUSIONS: HIV infected individuals had higher NT-proBNP levels than age matched blood donors possibly as a result of a higher prevalence of general cardiovascular risk factors and HIV associated risk factors, the finding is consistent with an increased incidence of cardiovascular events described in HIV infected individuals. Further studies on the relationship to cardiovascular outcome are warranted.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app